MedTrace Logo

BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors

NCT06368960 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-04-16

No results posted yet for this study

Summary

This is a non-randomized，open-label，controlled multi-center Phase Ⅰ study to evaluate tolerability, pharmacokinetics, and preliminary efficacy of BM201 injection in combination with radiotherapy in patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors who have failed standard therapy or are unable to receive standard treatment.

Conditions

Interventions

RADIATION

Radiotherapy

Radiation： Hypofractionated radiotherapy

DRUG

BM201 injection

BM201 injection：Dose escalation：24mg to 240mg

Sponsors & Collaborators

  • InnoBM Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Baorui L Chief Physician, PH.D · Nanjing Drum Towel Hospital /The Affiliated Hospital of Nanjing University Medical School

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-07
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06368960 on ClinicalTrials.gov